Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Cybin ( (TSE:CYBN) ).
Cybin Inc. announced that its CEO, Doug Drysdale, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference. This participation highlights Cybin’s active engagement in the industry and its commitment to advancing mental health treatments, potentially enhancing its visibility and influence in the neuropsychiatry field.
The most recent analyst rating on (TSE:CYBN) stock is a Buy with a C$114.00 price target. To see the full list of analyst forecasts on Cybin stock, see the TSE:CYBN Stock Forecast page.
Spark’s Take on TSE:CYBN Stock
According to Spark, TipRanks’ AI Analyst, TSE:CYBN is a Underperform.
Cybin’s stock score is significantly impacted by its lack of revenue and continuous financial losses, resulting in a low valuation score. While technical indicators are neutral, positive corporate events indicate potential for future growth. However, current financial challenges remain the dominant concern.
To see Spark’s full report on TSE:CYBN stock, click here.
More about Cybin
Cybin is a clinical-stage neuropsychiatry company focused on revolutionizing mental healthcare by developing innovative next-generation treatment options. The company is engaged in creating treatments for mental health conditions and is currently advancing CYB003 and CYB004, proprietary compounds for major depressive disorder and generalized anxiety disorder, respectively. Founded in 2019, Cybin operates in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.
Technical Sentiment Signal: Hold
Current Market Cap: C$1.97M
See more insights into CYBN stock on TipRanks’ Stock Analysis page.